Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 20/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317801 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| Cadaverine Tartrate SCHEMBL4320050 | 0.91 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3 | |
| Cadaverine Tartrate SCHEMBL4321029 | 0.91 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4336860 | 0.86 | SLC6A4 (0.65) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4324494 | 0.82 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4321162 | 0.82 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL13613069 | 0.81 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL13613083 | 0.81 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4489401 | 0.80 | SLC6A2 (0.86) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4483148 | 0.80 | SLC6A2 (0.86) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | SLC6A2, TPH1, SLC6A3 | SLC6A2 1/4885SLC6A4 8/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.